Jay Olson
Stock Analyst at Oppenheimer
(4.27)
# 359
Out of 5,173 analysts
248
Total ratings
45.5%
Success rate
18.46%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Outperform | $44 → $36 | $4.34 | +729.49% | 5 | Mar 18, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $540 → $600 | $451.24 | +32.97% | 2 | Mar 10, 2026 | |
| BIOA BioAge Labs | Initiates: Outperform | $60 | $18.63 | +222.06% | 1 | Feb 25, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $21 → $23 | $20.99 | +9.58% | 16 | Feb 6, 2026 | |
| BIIB Biogen | Maintains: Outperform | $205 → $225 | $183.64 | +22.52% | 26 | Jan 30, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $75 → $150 | $96.63 | +55.23% | 10 | Jan 27, 2026 | |
| CHRS Coherus Oncology | Initiates: Outperform | $10 | $1.64 | +509.76% | 1 | Jan 22, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $250 → $750 | $294.11 | +155.01% | 3 | Dec 15, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $28 → $58 | $49.61 | +16.91% | 4 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $600 → $650 | $447.72 | +45.18% | 12 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $2.21 | +126.24% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $90 | $70.79 | +27.14% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $30 | $5.12 | +485.94% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $3.39 | +312.98% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.82 | - | 15 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $3.60 | +1,705.56% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $65 | $1.19 | +5,362.18% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $1.61 | +707.45% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $74.34 | +21.07% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $21.09 | +99.15% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $41.41 | -20.31% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $13.11 | +205.11% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $6.76 | +195.86% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $4.88 | +514.75% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $90.45 | -9.34% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $32.55 | +323.96% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.89 | +323.28% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $349.77 | +8.64% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $127.05 | +72.37% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.40 | +400.00% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.88 | +363.92% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 | $21.33 | +368.82% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $46.88 | +102.65% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $0.64 | +3,795.29% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.13 | +696.46% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.33 | +37,493.98% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $12.65 | +66.01% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.86 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $16.88 | +397.63% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.31 | - | 3 | Jul 11, 2017 |
Bicycle Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $44 → $36
Current: $4.34
Upside: +729.49%
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Outperform
Price Target: $540 → $600
Current: $451.24
Upside: +32.97%
BioAge Labs
Feb 25, 2026
Initiates: Outperform
Price Target: $60
Current: $18.63
Upside: +222.06%
ACADIA Pharmaceuticals
Feb 6, 2026
Maintains: Perform
Price Target: $21 → $23
Current: $20.99
Upside: +9.58%
Biogen
Jan 30, 2026
Maintains: Outperform
Price Target: $205 → $225
Current: $183.64
Upside: +22.52%
Revolution Medicines
Jan 27, 2026
Maintains: Outperform
Price Target: $75 → $150
Current: $96.63
Upside: +55.23%
Coherus Oncology
Jan 22, 2026
Initiates: Outperform
Price Target: $10
Current: $1.64
Upside: +509.76%
Praxis Precision Medicines
Dec 15, 2025
Maintains: Outperform
Price Target: $250 → $750
Current: $294.11
Upside: +155.01%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $28 → $58
Current: $49.61
Upside: +16.91%
Madrigal Pharmaceuticals
Nov 20, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $447.72
Upside: +45.18%
Oct 21, 2025
Initiates: Outperform
Price Target: $5
Current: $2.21
Upside: +126.24%
Oct 8, 2025
Maintains: Outperform
Price Target: $84 → $90
Current: $70.79
Upside: +27.14%
Sep 25, 2025
Maintains: Outperform
Price Target: $21 → $30
Current: $5.12
Upside: +485.94%
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $3.39
Upside: +312.98%
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $8.82
Upside: -
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $3.60
Upside: +1,705.56%
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $1.19
Upside: +5,362.18%
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.61
Upside: +707.45%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $74.34
Upside: +21.07%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $21.09
Upside: +99.15%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $41.41
Upside: -20.31%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $13.11
Upside: +205.11%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $6.76
Upside: +195.86%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $4.88
Upside: +514.75%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $90.45
Upside: -9.34%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $32.55
Upside: +323.96%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.89
Upside: +323.28%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $349.77
Upside: +8.64%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $127.05
Upside: +72.37%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.40
Upside: +400.00%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.88
Upside: +363.92%
May 15, 2024
Maintains: Outperform
Price Target: $100
Current: $21.33
Upside: +368.82%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $46.88
Upside: +102.65%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $0.64
Upside: +3,795.29%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.13
Upside: +696.46%
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.33
Upside: +37,493.98%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $12.65
Upside: +66.01%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.86
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $16.88
Upside: +397.63%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $2.31
Upside: -